Latest Content

In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS releases new guidance aimed at lowering prescription drug costs through direct-to-consumer programs, and AstraZeneca enters a multibillion-dollar collaboration with CSPC Pharmaceutical Group.

The collaboration highlights how pharmaceutical companies are pairing capital and global infrastructure with platform technologies that deliver differentiated dosing and durability.

The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving immune responses at their source.

How demand-driven development will help new products be more successful.

DTP programs are redefining the manufacturer’s access operating model.

Teva’s VP of US innovative medicines marketing discusses the origins of the company’s new campaign featuring comedian Will Forte.

In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly integrated healthcare solutions, questions emerge around U.S. funding tied to global vaccine policy shifts, and the FDA approves a new treatment option for adults with presbyopia.

The guidance provides clarity to drug manufacturers on offering lower drug prices directly to patients, including patients on Medicare and Medicaid.

Public Citizen’s lawsuit highlights broader concerns over government transparency and oversight in pharmaceutical policy.

In the final part of his conversation with Pharmaceutical Executive, Clay Siegall (president and CEO of Immunome) details the next steps for his upcoming medication.

The preservative, which contains a form of Mercury, has long been the target of anti-vaccine groups, despite studies demonstrating its safety.

EVERSANA president Greg Skalicky continues the conversation, providing details about the commercialization strategy.

As precision medicine shifts from promise to practice, true patient impact will depend less on standalone drugs and more on whether pharma, MedTech, and diagnostics can finally converge to build integrated systems of care.